Presentations
Neola Medical regularly participates in capital market days and investor events to present our progress and milestones. Below you will find recordings from recent presentations, held in either English or Swedish.
Redeye Interview: Neola Medical Q4 2025 with CEO Hanna Sjöström
In a new interview with Redeye analyst Gustaf Meyer, CEO Hanna Sjöström discusses the key milestones from Neola Medical’s Q4 2025 report. Watch the full interview here: Redeye Interview Neola Medical Q4 2025 with CEO Hanna Sjöström Access additional insights from...
Neola Medical’s Q4 report presentation hosted by Investor Studios
Catch up on the highlights from Neola Medical’s year-end Q4 report for 2025. CEO Hanna Sjöström reflects on a year marked by key milestones as we entered the clinical phase, strengthened the organization, and continued to build on our most strategically important...
Redeye Interview Q2 2025 with CEO Hanna Sjöström
In a new interview with Redeye’s Gustaf Meyer, CEO Hanna Sjöström reflects on Q2 achievements and the road ahead. Redeye also provided a research update, raising their fair value range, now with a base case of SEK 3.3 (3.2). Watch the full interview here: Redeye...
Did you miss Neola Medical’s Q2 2025 report presentation?
Catch up on Neola Medical’s Q2 2025 highlights, including the successful enrollment of the first preterm born baby in the clinical pilot study in Sweden and advancing preparations for the pivotal U.S. clinical study. CEO Hanna Sjöström shares insights into these...
CEO Hanna Sjöström on Clinical and Strategic Milestones – Redeye Interview Q1 2025
Following a strengthened shareholder base and the first baby enrolled in Neola Medical’s Swedish clinical pilot study, CEO Hanna Sjöström joins Redeye to discuss recent milestones and what lies ahead. She shares insights into the company’s clinical progress, recent...
Redeye Interview: Neola Medical Strengthens Ownership Base with Institutional Investors
In an interview with Redeye, CEO Hanna Sjöström, discusses the company’s latest capital raise of approximately SEK 20 million and its significance for the future. For the first time, the company has attracted institutional investors, Cicero Funds and Adrigo Funds,...
Redeye Interview Q4 2024 with CEO Hanna Sjöström
Following the release of Neola Medical’s Q4 2024 report, Redeye Equity Research Analyst Gustaf Meyer interviewed CEO Hanna Sjöström to discuss key takeaways, the company’s progress toward the clinical phase, and the upcoming first clinical study on preterm born...
Did you miss Neola Medical’s Q4 2024 report presentation?
Catch up on key insights into Neola Medical’s latest developments as we prepare for clinical studies and continue strengthening our presence in the U.S. market. CEO Hanna Sjöström provides an update on key milestones and strategic progress in the U.S. and looks...
Highlights from Neola Medical’s Presentation at Redeye Technology & Life Science Day
Earlier this week, Neola Medical participated in the Redeye Technology and Life Science Day in Stockholm, showcasing the company’s significant progress and outlining its future plans during an engaging presentation and dynamic Q&A session. Discover deeper insights...
Neola Medical’s presentation at Stora Aktiedagarna in Stockholm
Yesterday CEO Hanna Sjöström showcased Neola Medical’s vision and strategic advancements during the presentation at Stora Aktiedagarna in Stockholm, highlighting the future of neonatal care. The presentation was met with great interest, filling the room with...
Stay updated on our progress and milestones
Neola Medical is currently in clinical phase with Neola®, undergoing our first clinical study on preterm born babies in Sweden. As the company approaches commercial launch, the focus is on securing market authorization in the U.S., followed by Europe.